Featured
User access denied after block
Gut Checks Aug 12, 2026
Rest Logs Aug 11, 2026
Mind Health Aug 10, 2026
The FDA will review tau PET imaging agent MK-6240 on August 13, seeking better Alzheimer...
Burnout in nurses increases missed care risks, especially in neuro-oncology, with resilience and professional identity...
Learn about multiple sclerosis treatment and factors influencing discontinuation of disease-modifying therapy for ms patients...
Read our latest Gut Checks articles.
Spinal muscular atrophy treatment breakthroughs extend lives, but healthcare systems struggle to adapt to new...
New data regarding CIDP treatment with efgartigimod PH20 reveals long-term patient outcomes for clinicians based...
Discover latest multiple sclerosis research and clinical trials at the forefront of medical science for...
Spinal muscular atrophy treatment breakthroughs extend lives, but healthcare systems struggle to adapt to new patient needs.
Spinal muscular atrophy treatment breakthroughs extend lives, but healthcare systems struggle to adapt to new patient needs.
Discover the latest spinal muscular atrophy treatment options, including nusinersen and onasemnogene abeparvovec, for patients with SMA.
Discover the latest developments in Spinal Muscular Atrophy treatment during SMA Awareness Month, highlighting new disease-modifying therapies.
Takeda's oveporexton approved for narcolepsy type 1 treatment as first medicine to target orexin signaling directly.
Lennox-Gastaut syndrome presents complex care challenges. Learn about treatment advancements and how to plan for a longer life for patients...
Thymidine kinase deficiency approval brings new hope as drugs doxecitine and doxribtimine receive regulatory clearance, improving survival for patients.
The FDA will review tau PET imaging agent MK-6240 on August 13, seeking better Alzheimer disease diagnosis by detecting tau...
New data regarding CIDP treatment with efgartigimod PH20 reveals long-term patient outcomes for clinicians based on recent clinical study data.
Aspen Neuroscience's sasineprocel receives FDA RMAT designation for Parkinson disease, accelerating development and potentially enabling accelerated approval.
High-dose NAC treatment shows promise in reducing brain damage markers in progressive MS patients, according to a new clinical trial.